Bayrou was appointed as the new Prime Minister of France. French public opinion regards him as a staunch political ally of Macron. The Elysee Palace, the French presidential palace, announced on the 13th that President Macron appointed francois bayrou, chairman of the Democratic Movement Party, as the new Prime Minister on the same day, replacing Banier, who resigned after being impeached by the National Assembly. According to French media reports, Macron had a telephone conversation with Bayrou on the evening of 12th, and on the morning of 13th, Macron met Bayrou in the presidential palace and talked again. Macron subsequently announced the appointment decision. Bayrou became the fourth French prime minister this year. Beru founded the Democratic Movement Party, a centrist party, in 2007, and has served as its chairman ever since. In 2017, Bayrou announced that he would give up running for the French president, and formed an alliance with Macron, one of the popular candidates in the presidential election at that time and the chairman of the "Forward" movement, to fully support Macron's presidential election. In 2022, in the process of Macron's re-election, Bayrou led the Democratic Movement Party to continue to form an alliance with the ruling party. French public opinion regards Bayrou as a staunch political ally of Macron. (Xinhua News Agency)Weilai announced that the number of power exchanges had exceeded 60 million times. Weilai issued a document saying that as of 21:06:08 on December 13th, 2024, Weilai had changed power more than 60 million times! Thank you for your support and trust in Weilai.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.
Spot gold fell below $2,660 per ounce, down 0.77% in the day.Bei Ya raised the Amazon target price from $220.00 to $260.00.The EUR/USD of the euro against the US dollar rose by 0.50% in the day and is now reported at 1.0518.
Analysis: the potential weakness of Canada's manufacturing industry still exists. Forexlive: Canada's manufacturing industry rebounded strongly, mainly driven by petroleum products and automobiles. However, the year-on-year data decline shows that some potential weakness still exists.Market News: Trump's assistant asked Trump if it was possible to abolish the Federal Deposit Insurance Corporation (FDIC).Huitai Medical: Using raised funds and self-owned funds to increase capital of 700 million yuan to wholly-owned subsidiaries. Huitai Medical announced that the company held the 20th meeting of the second board of directors and the 17th meeting of the second board of supervisors on December 12, 2024, and reviewed and approved the Proposal on Using raised funds and self-owned funds to increase capital to wholly-owned subsidiaries. The company agreed to increase its capital by 700 million yuan to Shanghai Hongtong Industrial Co., Ltd., a wholly-owned subsidiary, of which 438 million yuan of interest-bearing loans provided to Shanghai Hongtong with raised funds were converted into capital increase, and 262 million yuan was increased with its own funds. After the capital increase is completed, the registered capital of Shanghai Hongtong will increase from RMB 18,489,300 to RMB 26,548,200, and it will remain a wholly-owned subsidiary of the company.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14